Reset filter
Keywords
Myelodysplastic Syndromes ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

88 Search results.
Relevance Rating New first Old first

Eligibility Leukemia NCT01378416

- 4/20/17 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT01378416

Eligibility Leukemia, Myeloid, Chronic NCT00167167

- 2/6/16 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00167167

Eligibility Acute Biphenotypic Leukemia NCT01804101

- 12/2/15 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01804101

Eligibility DRKS00006115 NCT00822393 Acute Myeloid Leukemia - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 24 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00822393

Leukemia NCT00045305 Eligibility - E1902 Registration Worksheet (step 1) - 2950125v1.0 - E1902 Registration Worksheet (step 1)

- 9/17/21 - 1 form, 3 itemgroups, 35 items, 1 language
Itemgroups: Eligibility, Race, Patient Demographics / Pre-Treatment Characteristics
E1902 Registration Worksheet (step 1) Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=74FABE90-2003-D4A5-E040-BB89AD43500C

Eligibility Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome NCT02438761

- 2/7/16 - 1 form, 2 itemgroups, 30 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT02438761

EWOG MDS 2006 Severe complications after day 100 DRKS00003789 - Severe complications after day 100

- 8/5/14 - 1 form, 11 itemgroups, 24 items, 2 languages
Itemgroups: Show identification of patient, Severe infection occurred, Severe pulmonary complications, Severe cardio-vascular complications, Severe renal complications, Severe hepatic complications, Severe neurological complications, Severe gastrointestinal complications, Severe endocrinologic complications, Severe sceletal complications, Other severe complications
Prospective non–randomized multi​center study for epidemiology and characterization of Myelodysplastic Syndromes(MDS) and Juvenile Myelomonocytic Leukemia (JMML) in child­hood. PI: Prof. Dr. Charlotte Niemeyer http://clinicaltrials.gov/ct2/show/NCT00662090 http://www.ewog-mds.org/

Eligibility Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome NCT01238211

- 2/16/16 - 1 form, 1 itemgroup, 11 items, 1 language
Itemgroup: Inclusion Criteria
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01238211

Leukemia NCT00843882 On-Study - E2905 Baseline Step 2 Disease Evaluation Form - 2774237v1.0 - Baseline Step 2 Disease Evaluation Form (E2905 NCT00843882)

- 3/13/15 - 1 form, 4 itemgroups, 40 items, 1 language
Itemgroups: Header, Pre-registration Hematology/chemistry, Bone marrow biopsy, IPSS
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia NCT00843882 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=54590A88-E5FE-3BDA-E044-0003BA3F9857

EWOG MDS 2006 Severe complications till day +100 DRKS00003789 - Severe complications till day +100

- 8/5/14 - 1 form, 10 itemgroups, 20 items, 2 languages
Itemgroups: Show identification of patient, Severe infection occurred, Severe pulmonary complications, Severe cardio-vascular complications, Severe renal complications, Severe hepatic complications, VOD, Severe neurological complications, Severe gastrointestinal complications, Other severe complications
Prospective non–randomized multi​center study for epidemiology and characterization of Myelodysplastic Syndromes(MDS) and Juvenile Myelomonocytic Leukemia (JMML) in child­hood. PI: Prof. Dr. Charlotte Niemeyer http://clinicaltrials.gov/ct2/show/NCT00662090 http://www.ewog-mds.org/

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS) - On-Study Form - RelapseRefractory Treatment 2019378_v3_0 - Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) - On-Study Form - Relapse/Refractory Treatment

- 1/9/15 - 1 form, 4 itemgroups, 28 items, 2 languages
Itemgroups: CRF Header, AML/MDS: Form Administration, AML/MDS: Disease Description, Comments
Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) - On-Study Form - Relapse/Refractory Treatment Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B24FD93-54A8-51C5-E044-0003BA3F9857

EWOG MDS 2006 Status Day 30 DRKS00003789 - Status Day 30

- 8/5/14 - 1 form, 15 itemgroups, 57 items, 2 languages
Itemgroups: Show identification of patient, Complications - Infection, Complications - EBV PCR, Complications - EBV LPD, Complications - EBV LPD symptoms, Complications - EBV LPD site, Complications - EBV LPD treatment, Complications - Hemorrhage, Complications - Renal/Metabolic Lab., Creatinine, Complications - Other type of complication, Transfusions, Transfusion PLT, Transfusion RBC, Complete blood count, Study centre specific variables
Prospective non–randomized multi​center study for epidemiology and characterization of Myelodysplastic Syndromes(MDS) and Juvenile Myelomonocytic Leukemia (JMML) in child­hood. PI: Prof. Dr. Charlotte Niemeyer http://clinicaltrials.gov/ct2/show/NCT00662090 http://www.ewog-mds.org/

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial